Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 58Squamous Cell Carcinoma of Head and Neck 37Nasopharyngeal Carcinoma 27Lung Neoplasms 25Uterine Cervical Neoplasms 22Biliary Tract Neoplasms 22Esophageal Squamous Cell Carcinoma 20Oropharyngeal Neoplasms 18Head and Neck Neoplasms 17Cholangiocarcinoma 17Urinary Bladder Neoplasms 14Neoplasms 14Neoplasm Metastasis 14Ovarian Neoplasms 13Esophageal Neoplasms 12Carcinoma 12Colorectal Neoplasms 11Stomach Neoplasms 10Small Cell Lung Carcinoma 10Carcinoma, Transitional Cell 8Mouth Neoplasms 7Laryngeal Neoplasms 7Hypopharyngeal Neoplasms 7Carcinoma, Squamous Cell 7Recurrence 6Nasopharyngeal Neoplasms 5Gallbladder Neoplasms 5Endometrial Neoplasms 5Breast Neoplasms 5Bile Duct Neoplasms 5

Interventions

X-Rays 1Taxes 1Specimen Handling 1Platinum 1Paclitaxel 1Etoposide 1Cisplatin 1Carboplatin 1Biopsy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Advanced NUT Carcinoma × Cisplatin × Clear all
NCT05019716 2026-05-13

Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma

National Cancer Institute (NCI)

Phase 1/2 Recruiting
36 enrolled

Advanced NUT Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡